scholarly journals An open label single arm prospective clinical study on Vatagajankusha Rasa with Pippali Churna and Manjishta Kwatha as Anupana in Pakshaghata (CVA due to Infarct)

2019 ◽  
Vol 4 (06) ◽  
Author(s):  
Yadu Gopan ◽  
Totad Muttappa ◽  
Vasantha B. ◽  
Kiran K.
Keyword(s):  
Clinical Study ◽  
Outcome Measures ◽  
Ordinal Data ◽  
Secondary Outcome ◽  
Prospective Clinical Study ◽  
Rank Tests ◽  
Open Label ◽  
Signed Rank ◽  
Non Parametric

Background: Pakshaghata is one among the 80 vataja nanatmaja vikara and is a roga of madhyama roga marga. Vatavyadhi is considered to be one among the ashta mahagadas. Vatagajankusha rasa is a combination of vyosha, bhasmas, vatsanabha, karkatasringi, haritaki etc. It has vatakaphahara, vikasi, vyavayi, rasayana etc properties. It is said to be effective in treating pakshaghata in 7 days if given along with Pippali churna and Manjishta kwatha. Aims and Objectives: To evaluate the efficacy of Vatagajankusha rasa with Pippali churna and Manjishta kwatha as anupana in the management of pakshaghata (CVA due to infarct). Methodology: Among 32 registered patients, 30 completed the course of treatment. They were administered with Vatagajankusha rasa 1 tablet (125 mg) after food with anupana 3gm Pippali churna and 15 ml Manjishta kwatha twice daily (morning and evening) for a period of 7 days. Nominal and ordinal data were analysed using non parametric tests like McNemar and Wilcoxon’s signed rank tests respectively. Result: There was statistically significant improvement in the primary and secondary outcome measures (p less than 0.05 was observed). Conclusion: Vatagajankusha rasa with Pippali churna and Manjishta kwatha as anupana is effective in the management of Pakshaghata (CVA due to infarct).

scholarly journals An open label single arm prospective clinical study on Vatagajankusharasa with Pippali Churna and Manjishta Kwatha as Anupana in Viswachi (cervical spondylosis)

2020 ◽  
Vol 5 (01) ◽  
pp. 73-80
Author(s):  
Moh Gulfam ◽  
Totad Muttappa ◽  
Neelam Bisht ◽  
Vishnu M L ◽  
Yadu Gopan
Keyword(s):  
Clinical Study ◽  
Ordinal Data ◽  
Cervical Spondylosis ◽  
Signs And Symptoms ◽  
Upper Extremities ◽  
Secondary Outcome ◽  
Prospective Clinical Study ◽  
Rank Tests ◽  
Open Label ◽  
Signed Rank

Background: Viswachi is one among the 80 Nanatmaja Vata Vyadhi. This disease affects the neck and upper extremities with the signs and symptoms like Ruk, Stambha, Toda, Bahu Karmakshaya. Vatagajankusha Rasa is a combination of Vyosha, Bhasmas, Vatsanabha, Karkatasringi, Haritaki etc. It has Vatakaphahara, Vikasi, Vyavayi, Rasayana etc. properties. It is said to be effective in treating Visawachi in 7 days if given along with Pippali Churna and Manjishta Kwatha. Aims and Objectives: To evaluate the efficacy of Vatagajankusha Rasa with Pippali Churna and Manjishta Kwatha as Anupana in the management of Viswachi (Cervical spondylosis). Methodology: Among 35 registered patients, 30 completed the course of treatment. They were administered with Vatagajankusha Rasa 1 tablet (125 mg) after food with Anupana 3gm Pippali Churna and 15 ml Manjishta Kwatha twice daily (morning and evening) for a period of 7 days. Nominal and ordinal data were analysed using non parametric tests like McNemar and Wilcoxon’s signed rank tests respectively. Result: Assessment parameters like Ruk, Toda, Sthambha and Bahukarma Kshya. There was statistically significant improvement in the primary and secondary outcome measures (p less than 0.05 was observed). Conclusion: Vatagajankusha Rasa with Pippali Churna and Manjishta Kwatha as Anupana is effective in the management of Viswachi (Cervical spondylosis).

scholarly journals An open label single arm prospective clinical study in the management of Pakshaghata (CVA due to infarct) with Maharasnadi Kashaya and Shunti Churna

2020 ◽  
Vol 5 (05) ◽  
pp. 59-64
Author(s):  
Rohan Mohandas ◽  
Muttappa Totad ◽  
Vasantha B ◽  
Sphoorthi Narasimhan
Keyword(s):  
Clinical Study ◽  
Outcome Measures ◽  
Sampling Method ◽  
Primary Outcome ◽  
Tertiary Hospital ◽  
P Value ◽  
Prospective Clinical Study ◽  
Open Label ◽  
Scale Parameters ◽  
Maximum Improvement

Pakshaghata is one among 80 Vata Namathmaja Vyadhi. In Pakshaghata vitiated Vata resides in one half of body and causes Vishoshana of Sira and Snayu leading to loosening of joints results into manifestation of symptoms like Cheshta Nivrutti, Ruja and Vakstambha. Pakshaghata can be correlated to stroke or CVA. The study aims to evaluate the combined effectiveness of Maharasnadi Kashaya with Shunti Churna as Anupana in management of Pakshaghata (CVA due to infarct). The open label prospective clinical study was conducted among the 32 patients of Pakshaghata by convenient sampling method at a tertiary Hospital Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital, Hassan, Karnataka from December 2018 to December 2019. The effectiveness of the drug showed improvement in primary outcome measures such as Cheshta Nivrutti, Vakstambha and Ruk in subjects of Pakshaghata with p value less than 0.05. In this study, maximum improvement was found in “Ruk” followed by “Cheshta Nivrutti” and then “Vak Stambha”. Hence this drug is more effective in “Saruja Pakshaghata” hence; it showed improvement in the NIH stroke scale parameters with p value less than 0.05. The combined effectiveness of Maharasnadi Kashaya with Shunti Churna as Anupana in management of Pakshaghata (CVA due to Infarct) is proved.

scholarly journals Effects of Collagen Hydrolysates on Human Brain Structure and Cognitive Function: A Pilot Clinical Study

Nutrients ◽  
2019 ◽  
Vol 12 (1) ◽  
pp. 50
Author(s):  
Seiko Koizumi ◽  
Naoki Inoue ◽  
Fumihito Sugihara ◽  
Michiya Igase
Keyword(s):  
Cognitive Function ◽  
Outcome Measures ◽  
Brain Structure ◽  
Short Form ◽  
Gray Matter Volume ◽  
Rank Correlation ◽  
Secondary Outcome ◽  
Open Label ◽  
Associate Learning ◽  
Collagen Hydrolysates

This study investigated the effects of collagen hydrolysates (CH) on language cognitive function and brain structure. In this open-label study, 5 g CH was administered once a day for 4 weeks to 30 healthy participants aged 49–63 years. The primary outcome measures were the brain healthcare quotients based on gray matter volume (GM-BHQ) and fractional anisotropy (FA-BHQ). The secondary outcome measures were changes in scores between week 0 and week 4 for word list memory (WLM) and standard verbal paired associate learning (S-PA) tests as well as changes in the physical, mental, and role/social component summary scores of the Short Form-36(SF-36) quality of life instrument. CH ingestion resulted in significant improvements in FA-BHQ (p = 0.0095), a measure of brain structure, as well in scores for the WLM (p = 0.0046) and S-PA (p = 0.0007) tests, which measure cognitive function. There were moderate correlations between the change in WLM score and the change in GM-BHQ (r = 0.4448; Spearman’s rank correlation) and between the change in S-PA score and the change in FA-BHQ (r = 0.4645). Daily ingestion of CH changed brain structure and improved language cognitive function.

scholarly journals Douching With Water Works Device for Perceived Vaginal Odor With or Without Complaints of Discharge in Women With No Infectious Cause of Vaginitis: A Pilot Study

2006 ◽  
Vol 2006 ◽  
pp. 1-4 ◽  
Author(s):  
Ashwin J. Chatwani ◽  
Sarmina Hassan ◽  
Salma Rahimi ◽  
Stacey Jeronis ◽  
Vani Dandolu
Keyword(s):  
Pilot Study ◽  
Outcome Measures ◽  
Primary Outcome ◽  
Secondary Outcome ◽  
Open Label ◽  
Significant Change

Objective. To determine if douching with Water Works device for 1 month can (1) lower or eliminate perceived vaginal odor by subject; (2) have any effects on vaginal ecosystem.Methods. Ten women with perceived vaginal odor with or without discharge, douched every day for 4 weeks in an open-label, nonrandomized pilot study. Primary outcome measures included perceived vaginal odor by subject, lactobacilli score from Nugent slide, and acceptance of the Water Works douching system. Secondary outcome included the safety of using this douching device.Results. At week 4, there was improvement in vaginal odor (P=.0006) and there was no significant change in lactobacilli score.Conclusion. Douching with Water Works device is associated with reduction or elimination of vaginal odor without adversely affecting the vaginal ecosystem.

scholarly journals Montelukast as an Alternative to Low-Dose Inhaled Corticosteroids in the Management of Mild Asthma (The SIMPLE Trial): An Open-Label Effectiveness Trial

2009 ◽  
Vol 16 (suppl a) ◽  
pp. 11A-16A ◽  
Author(s):  
R Andrew McIvor ◽  
Alan Kaplan ◽  
Caroline Koch ◽  
John S Sampalis
Keyword(s):  
Asthma Control ◽  
Outcome Measures ◽  
Low Dose ◽  
Inhaled Corticosteroids ◽  
Symptom Control ◽  
Physician Satisfaction ◽  
Mild Asthma ◽  
Secondary Outcome ◽  
Open Label ◽  
Number Of Patients

OBJECTIVE: To evaluate the effectiveness of montelukast as monotherapy for patients with mild asthma who remain uncontrolled or unsatisfied while on inhaled corticosteroid (ICS) monotherapy.DESIGN: A multicentre, open-label study. Patients (six years of age or older) had ICS therapy discontinued and were treated with orally administered montelukast once daily for six weeks.MAIN OUTCOME MEASURES: The primary outcome measure was the rate at which asthma symptom control was achieved or maintained after six weeks of treatment. The secondary outcome measures were to compare compliance and physician satisfaction, and to further assess the safety and tolerability of montelukast.RESULTS: Of the 534 patients enrolled, 481 (90.1%) completed the study. Mean (± SD) age was 27.8±19.0 years. The number of patients with uncontrolled symptoms decreased from 455 (85.2%) at baseline to 143 (26.8%) at week 6 (P<0.001), and mean Asthma Control Questionnaire score decreased from 1.4±0.8 to 0.6±0.6 (P<0.001), representing a clinically significant improvement. Of the 79 patients with controlled asthma symptoms at baseline, 73.4% maintained asthma control at week 6. Compliance to asthma therapy increased from 41% at baseline for ICS to 88% at week 6 for montelukast (P<0.001). Physician satisfaction with treatment increased from 43% to 85% (P<0.001) and patient satisfaction increased from 45% at baseline to 94% at week 6. No serious adverse events were reported over the course of the study.CONCLUSION: Montelukast is an effective and well-tolerated alternative to ICS treatment in patients with mild asthma who are uncontrolled or unsatisfied with low-dose ICS therapy.

scholarly journals Influence of Implant Thread Morphology on Primary Stability: A Prospective Clinical Study

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Maria Menini ◽  
Francesco Bagnasco ◽  
Ivan Calimodio ◽  
Nicolò Di Tullio ◽  
Francesca Delucchi ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Outcome Measures ◽  
Primary Stability ◽  
Secondary Outcome ◽  
Prospective Clinical Study ◽  
Insertion Torque ◽  
Significant Difference ◽  
Group 5 ◽  
One Year ◽  
Torque Values

Objectives. The purpose of this study was to evaluate the primary stability of two implants with the same macro- and micromorphology but different thread design and analyze their clinical outcomes over a one-year period. Materials and Methods. 14 patients needing a partial rehabilitation with a delayed loading approach (DEL group: 9 patients) or a full-arch rehabilitation treated with immediately loaded fixed prostheses supported by 4 implants following the Columbus Bridge Protocol (CBP) (IL group: 5 patients) were included. In each patient, at least one SY (implant with standard threads) and one SL implant (implant with an augmented depth of the threads) were randomly inserted. Primary outcome measures were the number of threads exposed at a torque of 30 Ncm and 50 Ncm and final insertion torque. Secondary outcome measures were implant and prosthetic failure, peri-implant bone resorption, and periodontal parameters: bleeding on probing (BoP), plaque index (PI), and probing depth (PD) evaluated at 3, 6, and 12 months of healing. Results. Nineteen SY and 19 SL implants were inserted in 14 patients. Twenty implants (10 SL and 10 SY) were inserted in the IL group, while 18 (9 SL and 9 SY) were inserted in the DEL group and followed-up for 12 months. No patients dropped out. No implants and prostheses failed. No biological complications were identified. No significant differences were found between SY and SL implants comparing the number of exposed threads when inserting the implant with a torque insertion of 30 N (T student test p=.142 and U test p=.164). At 50 N, no threads were visible in either groups. Final torque insertion values were higher for SL (mean: 48.42 Ncm) compared to SY implants (mean: 43.42 Ncm) without a statistically significant difference. All the implants showed good clinical outcomes at the 1-year-in-function visit. Conclusions. After 12 months of function, both implant types provided good clinical outcomes without statistically significant differences between the two groups. A difference in insertion torque (even if not statistically significant) was found with higher insertion torque values for SL implants with a larger thread depth.

Efficacy and Safety of Traditional Chinese Medicine in COVID-2019: A Study Protocol for an Open-Label, Multicenter Randomized Controlled Trial

2020 ◽  
Author(s):  
Congcong Zeng ◽  
Zhengzhong Yuan ◽  
Xiaoqiong Pan ◽  
Jizhou Zhang ◽  
Jiahui Zhu ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Outcome Measures ◽  
Lung Injury Score ◽  
Secondary Outcome ◽  
Control Group ◽  
Efficacy And Safety ◽  
Open Label ◽  
Randomized Controlled

Abstract Introduction: The outbreak of a novel coronavirus (SARS-CoV-2) and associated COVID-19 disease in late December 2019 has led to a global pandemic. It directly leads to high morbidity and mortality, but also results in a devastating effect on the global economy. Unfortunately, there are no effective therapies or vaccines for it. Hence, we designed a randomized trial to evaluate the efficacy and safety of Traditional Chinese Medicine for treating patients with COVID-19.Methods and analysis: This is an open-label, multicenter randomized controlled clinical trial. One hundred and twelve patients infected by SARS-CoV-2 will be randomly assigned to the experimental or the control group in an equal ratio. The patients in control group will accept routine supportive clinically care including the therapies of anti-viral, anti-bacterial and ameliorating the related symptoms, while patients in the experimental group will be asked to take traditional Chinese medicine depending on the different stages of the disease for consecutive 14 days in addition to supportive care. All data will be gathered at baseline and on days 3, 7, 10 and 14. The primary outcome measures will be the time of Reverse Transcription PCR testing of respiratory tract sample turns to be negative. Secondary outcome measures will include Murray lung injury score, MuLBSTA score and TCM ( Traditional Chinese Medicine ) Syndrome Scoring System. A laboratory test will be taken before and after treatment to assess the safety of TCM.Discussion: The study may help to identify the the efficacy and safety of Traditional Chinese Medicine in treating COVID-2019.Trial registration: Chinese Clinical Trial Registry, ChiCTR2000030759.Registered on March 13th 2020-Retrospectively registered, http://www.chictr.org.cn/.

scholarly journals Redefining face contour with a novel anti-aging cosmetic product: an open-label, prospective clinical study

2017 ◽  
Vol Volume 10 ◽  
pp. 473-482 ◽  
Author(s):  
Aurora Garre ◽  
Gemma Martinez-Masana ◽  
Jaime Piquero-Casals ◽  
Corinne Granger
Keyword(s):  
Clinical Study ◽  
Prospective Clinical Study ◽  
Open Label ◽  
Cosmetic Product ◽  
Face Contour
Sign in / Sign up

Export Citation Format

Share Document